Early test for potential new myeloma drug begins
NCT ID NCT07400744
Summary
This is an early-stage study to see how a new drug called QL2109 compares to an existing drug, Darzalex, in healthy men. Researchers will measure how the body processes each drug and check for safety and immune reactions. The goal is to see if QL2109 behaves similarly to the approved drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.